Generic Semaglutide 2026: Where It's Available and What It Costs
Generic semaglutide reached India, Canada, and Brazil in 2026 at up to 90% off brand prices. What it costs, whether it works the same, and when the US gets it.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on August 3, 2026
Our medical review process ensures clinical accuracy and patient safety.
The most consequential event in obesity medicine this year was not a trial readout. It was a patent clock running out. Novo Nordisk's core semaglutide patents expired across India, Canada, Brazil, China, and Turkey during 2026, and generic semaglutide is now being dispensed in pharmacies where the branded product cost ten to a hundred times more twelve months ago.
The scale of the price collapse is hard to overstate. In India, where branded semaglutide ran roughly ₹10,000–16,000 per month, the cheapest approved generics launched near ₹1,290 — under $15. Canada became the first G7 country to approve a generic version, and the first products reached patients in May 2026.
For the roughly 65% of patients without type 2 diabetes who abandon GLP-1 therapy inside a year — a figure driven substantially by cost — this changes the arithmetic of long-term treatment.
What "Generic Semaglutide" Actually Means
Semaglutide is a peptide, not a small molecule like metformin, and not a large biologic like insulin glargine. That in-between status matters for how copies get approved.
In most markets, follow-on semaglutide is authorized as a generic — the manufacturer demonstrates the active ingredient is chemically identical and that the product delivers the same amount of drug into the bloodstream (bioequivalence), without repeating the full phase 3 program. This is the pathway Health Canada and India's CDSCO have used.
Three terms get confused constantly, and the distinction is clinical, not semantic:
| Product type | Regulator-approved? | Identical molecule? | Manufacturing oversight |
|---|---|---|---|
| Generic semaglutide | Yes — full marketing authorization | Yes, demonstrated bioequivalent | Full GMP inspection |
| Compounded semaglutide | No — prepared under compounding exemptions | Often a salt form never tested in trials | Limited; varies by pharmacy |
| Falsified semaglutide | No — criminal counterfeit | Unknown contents | None |
Only the first carries the regulatory guarantee that what is in the pen matches what was studied. Our review of compounded semaglutide covers why the middle column collapsed as a category once shortages resolved.
Where Generic Semaglutide Is Available in 2026
India
India's semaglutide patent lapsed on 20 March 2026, and the market moved within days. Sun Pharma, Zydus Lifesciences, and Alkem secured early approvals, with more than 40 domestic manufacturers reported to be preparing launches. Sun Pharma priced its version at roughly $8 per month against Novo Nordisk's $100-plus branded pricing in the same market.
India matters beyond its own borders. Indian manufacturers supply a large share of the world's generic medicines, and several — including Dr. Reddy's and Zydus — filed simultaneously in Canada, Turkey, and Brazil.
Canada
Health Canada approved the first generic semaglutide on 28 April 2026, making it the first G7 regulator to do so. Dr. Reddy's received authorization on 29 April and Apotex on 1 May; both launched on 14 May 2026. In June, Apotex's Sevmia was authorized specifically for the weight-management indication — the generic counterpart to Wegovy rather than Ozempic.
Additional filings from Teva, Taro, Sandoz, Hikma, Aspen, AA Pharma, and Zydus remain under Health Canada review. Sandoz has publicly committed to pricing up to 70% below the branded equivalent.
Brazil, China, and Elsewhere
Brazil, China, and Turkey all have 2026 expiry dates, with generic entries staged through the second half of the year. The commercial logic is the same everywhere: semaglutide is a high-volume, high-margin product with no remaining exclusivity, which is precisely the profile that attracts crowded generic entry.
What Generic Semaglutide Costs — and Why It Can Go Lower
Two peer-reviewed pricing analyses predicted this collapse years before it happened, and both suggest current generic prices still have room to fall.
Evidence: Cost-of-goods modelling found injectable semaglutide could be manufactured and sold at a profit for approximately $0.89 per month, against then-current global prices of $95–$353 per month — a markup of roughly 100- to 400-fold. — Barber MJ, et al. JAMA Netw Open. 2024. DOI
A separate analysis using a different method reached a directionally identical conclusion.
Evidence: A 30-day course of semaglutide ranged from $804 in the United States to $95 in Turkey, while the estimated minimum sustainable price was $40 per month. — Levi J, et al. Obesity. 2023;31(5):1270–1279. DOI
How fast real-world prices approach those floors depends almost entirely on how many manufacturers show up. The relationship is well characterized across 1.9 billion US prescription claims:
Evidence: With a single generic manufacturer, the generic price sat at 87% of the brand price. A second manufacturer dropped it to 77%, and a third to 60%. — Dave CV, Hartzema A, Kesselheim AS. N Engl J Med. 2017;377(26):2597–2598. DOI
This is why India's 40-plus entrants produced a 90% price cut while Canada's initial two-manufacturer market produced a more modest one. Canadian pricing should compress further as the pending filings clear review.
| Market | Status (Aug 2026) | Approximate monthly cost |
|---|---|---|
| India | Generic, 40+ entrants | ~$8–$20 |
| Canada | Generic, 2 launched, ~7 pending | 45–70% below brand |
| Brazil / China / Turkey | Rolling entry through 2026 | Not yet stable |
| United States | Brand only | $500–$1,000+ list |
Why the United States Has to Wait Until 2031
The single most common misconception is that a 2026 expiry elsewhere means cheap semaglutide is imminent in the US. It does not.
US patent term extensions — granted to compensate for FDA review time — pushed the core semaglutide composition patent to 5 December 2031, with the Wegovy-linked composition patent running to December 2032. Method-of-use and device patents, plus confidentially settled Hatch-Waxman litigation, create a realistic loss-of-exclusivity window somewhere between 2031 and 2033.
Personal importation does not close that gap. Bringing a foreign-approved generic into the US for personal use is generally unlawful and unenforceable as a supply strategy, and it forfeits the cold-chain and pharmacovigilance protections that make the generic safe in the first place. Patients facing US pricing are better served by working through insurance coverage pathways and manufacturer savings programs.
Do Generics Work as Well as Brand-Name Semaglutide?
Bioequivalence approval means the generic delivers the same active molecule at the same systemic exposure. The efficacy evidence therefore transfers from the originator trials rather than needing to be regenerated.
Those trials remain the benchmark for what any semaglutide product should achieve:
Evidence: In STEP 1, semaglutide 2.4 mg produced a mean body-weight change of −14.9% versus −2.4% with placebo at 68 weeks; 50.5% of treated participants lost at least 15% of body weight versus 4.9% on placebo. — Wilding JPH, et al. N Engl J Med. 2021;384(11):989–1002. DOI
Evidence: In SELECT, 17,604 adults with cardiovascular disease and overweight or obesity but no diabetes had a 20% reduction in major adverse cardiovascular events over a mean 39.8 months. — Lincoff AM, et al. N Engl J Med. 2023;389(24):2221–2232. DOI
Two practical caveats apply to generics specifically:
Device differences are real. Bioequivalence covers the drug, not the injector. Pen mechanics, dose-dial feel, needle gauge, and priming steps can differ between the brand and each generic. Anyone switching should be re-trained on the specific device rather than assuming their existing injection technique carries over.
Indication labelling differs by product. A generic approved against Ozempic carries a diabetes indication; one approved against Wegovy carries the weight-management indication and the higher 2.4 mg dose. These are not interchangeable at the pharmacy counter in most jurisdictions.
The Counterfeit Risk Rises With the Price Story
Cheap legitimate semaglutide and cheap fake semaglutide now compete for the same searches, and the second category is a documented, ongoing hazard.
The WHO issued Medical Product Alert N°2/2024 after falsified Ozempic batches entered regulated supply chains in Brazil, the United Kingdom, and the United States. Falsified injectables risk incorrect dosing, contamination, and unknown substituted ingredients — delivered subcutaneously, which makes the exposure difficult to reverse.
Three checks separate a legitimate generic from a counterfeit:
- It has a national marketing authorization. Apotex's Apo-Semaglutide and Sevmia, Dr. Reddy's, Sun Pharma's, and Zydus's products appear in their respective regulators' public databases. Verify the specific brand name in the country where it was dispensed.
- It comes from a licensed pharmacy. Not a social platform, a messaging app, or a website with no verifiable physical address and no prescription requirement.
- It requires a prescription. Every legitimate semaglutide product on earth does.
Products sold as "research grade," "semaglutide sodium," or shipped as lyophilized powder for self-reconstitution are outside all three categories.
What This Means for Long-Term Treatment
Obesity is a chronic, relapsing condition, and semaglutide's benefit is contingent on continued use. The dominant failure mode in real-world practice is not inefficacy — it is stopping.
Evidence: Among 125,474 US adults with overweight or obesity initiating GLP-1 therapy, 64.8% without type 2 diabetes discontinued within one year, versus 46.5% of those with diabetes. Reinitiation within a year was 36.3% and 47.3% respectively. — Rodriguez PJ, et al. JAMA Netw Open. 2025;8(1):e2457349. DOI
That discontinuation gradient tracks affordability closely: the group less likely to have insurance coverage is the group more likely to quit. Generic entry attacks that mechanism directly, which is a different and more durable intervention than any incremental gain in drug potency.
The World Health Organization added GLP-1 receptor agonists to its Model List of Essential Medicines in September 2025, covering type 2 diabetes with cardiovascular or kidney disease and obesity at BMI ≥30 kg/m². That listing is a lever for national procurement and price negotiation in exactly the low- and middle-income markets where 2026 generics are now landing.
Key Takeaways
- Semaglutide patents expired across India, Canada, Brazil, China, and Turkey in 2026; Canada was the first G7 country to approve a generic, on 28 April 2026
- Indian generics launched near $8–$15 per month against $100+ branded pricing; Canadian generics are 45–70% below brand with more entrants pending
- Peer-reviewed cost modelling puts the sustainable production price at $0.89–$40 per month, so current generic pricing still has room to fall
- Price declines track manufacturer count: prices reach 87%, 77%, and 60% of brand with one, two, and three generic makers respectively
- The US is not part of this — core patents run to December 2031, with realistic generic entry in the 2031–2033 window
- Approved generics are bioequivalent and inherit STEP 1 and SELECT efficacy; injector devices and labelled indications still differ by product
- Falsified semaglutide has reached regulated supply chains; verify marketing authorization, use a licensed pharmacy, and require a prescription
References
- Barber MJ, Gotham D, Bygrave H, Cepuch C. Estimated Sustainable Cost-Based Prices for Diabetes Medicines. JAMA Netw Open. 2024;7(3):e243474. DOI: 10.1001/jamanetworkopen.2024.3474
- Levi J, Wang J, Venter F, Hill A. Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. Obesity (Silver Spring). 2023;31(5):1270–1279. DOI: 10.1002/oby.23725
- Dave CV, Hartzema A, Kesselheim AS. Prices of Generic Drugs Associated with Numbers of Manufacturers. N Engl J Med. 2017;377(26):2597–2598. DOI: 10.1056/NEJMc1711899 PubMed
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. DOI: 10.1056/NEJMoa2032183
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–2232. DOI: 10.1056/NEJMoa2307563
- Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Netw Open. 2025;8(1):e2457349. DOI: 10.1001/jamanetworkopen.2024.57349 PubMed
- World Health Organization. Medical Product Alert N°2/2024: Falsified OZEMPIC (semaglutide). WHO. June 2024. WHO
- World Health Organization. WHO Model Lists of Essential Medicines — 24th List. WHO. September 2025. WHO
Last updated: 2026-08-03 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.